Safety and tolerability of donepezil 23 mg in moderate to severe alzheimer's disease

BMC Neurology

Volumn 11, Issue , 2011, Pages

  Farlow, Martin ^a   Veloso, Felix ^b   Moline, Margaret ^c   Yardley, Jane ^d   Brand Schieber, Elimor ^c   Bibbiani, Francesco ^c   Zou, Heng ^c   Hsu, Timothy ^c   Satlin, Andrew ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Saskatchewan Health Authority   (Canada)

^c EISAI INC   (United States)

^d EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; MEMANTINE; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ARTICLE; ASTHENIA; BODY WEIGHT; BRADYCARDIA; CONFUSION; CONTROLLED STUDY; CONTUSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; FALLING; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENDER; HEMATEMESIS; HEMATOCHEZIA; HUMAN; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MELENA; NAUSEA; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; SIDE EFFECT; SINUS BRADYCARDIA; SOMNOLENCE; SYNCOPE; URINARY TRACT INFECTION; URINE INCONTINENCE; VITAL SIGN; VOMITING; WEIGHT REDUCTION; AGE; CLINICAL TRIAL; EMERGENCY HEALTH SERVICE; HOSPITALIZATION; SEX DIFFERENCE; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BODY WEIGHT; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EMERGENCY SERVICES, PSYCHIATRIC; FEMALE; HUMANS; INDANS; MALE; PIPERIDINES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME;

EID: 80052615524     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-11-57     Document Type: Article

References (13)

1. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 2010, 32(7):1234-1251. 10.1016/j.clinthera.2010.06.019, 3068609, 20678673.
2. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal Bianco P, Stähelin HB, Hartman R, Gharabawi M, . on behalf of the B303 Exelon Study Group Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial [published erratum appears in: BMJ. 2001;322:1456]. BMJ 1999, 318(7184):633-638. 27767, 10066203, on behalf of the B303 Exelon Study Group.
3. Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 2004, 19(7):624-633. 10.1002/gps.1133, 15254918.
4. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002, 127:45-63.
5. Farlow MR, Alva G, Meng X, Olin JT. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Curr Med Res Opin 2010, 26(2):263-269. 10.1185/03007990903434914, 19929593.
6. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999, 10(3):237-244. 10.1159/000017126, 10325453.
7. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, . Donepezil Study Group A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998, 50(1):136-145. Donepezil Study Group.
8. Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P, . on behalf of the Donepezil MSAD Study Investigators Group Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Curr Med Res Opin 2002, 18(6):347-354. 10.1185/030079902125001029, 12442882, on behalf of the Donepezil MSAD Study Investigators Group.
9. Aricept Product Insert: ARICEPT® (donepezil hydrochloride) Tablets and ARICEPT® Orally Disintegrating Tablets. 2010, Aricept., http://aricept.com/pdf/AriceptComboFullPIFebruary2011.pdf
10. Nozawa M, Ichimiya Y, Nozawa E, Utumi Y, Sugiyama H, Murayama N, Iseki E, Arai H. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan. Psychogeriatrics 2009, 9(2):50-55. 10.1111/j.1479-8301.2009.00291.x, 19604325.
11. Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, Wetterholm AL, Haglund A, Zhang R, Schindler R. 3-Year study of donepezil therapy in Alzheimer disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006, 21:353-363. 10.1159/000091790, 16508298.
12. Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand SL, Rochon PA. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med 2009, 169(9):867-873. 10.1001/archinternmed.2009.43, 19433698.
13. Park-Wyllie LY, Mamdani MM, Li P, Gill SS, Laupacis A, Juurlink DN. Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. PLoS Med 2009, 6(9):e1000157. 10.1371/journal.pmed.1000157, 2742897, 19787032.